Molecular engineering of safe and efficacious oral basal insulin
Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2020-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-17487-9 |
| _version_ | 1818855593959489536 |
|---|---|
| author | Frantisek Hubálek Hanne H. F. Refsgaard Sanne Gram-Nielsen Peter Madsen Erica Nishimura Martin Münzel Christian Lehn Brand Carsten Enggaard Stidsen Christian Hove Claussen Erik Max Wulff Lone Pridal Ulla Ribel Jonas Kildegaard Trine Porsgaard Eva Johansson Dorte Bjerre Steensgaard Lars Hovgaard Tine Glendorf Bo Falck Hansen Maja Kirkegaard Jensen Peter Kresten Nielsen Svend Ludvigsen Susanne Rugh Patrick W. Garibay Mary Courtney Moore Alan D. Cherrington Thomas Kjeldsen |
| author_facet | Frantisek Hubálek Hanne H. F. Refsgaard Sanne Gram-Nielsen Peter Madsen Erica Nishimura Martin Münzel Christian Lehn Brand Carsten Enggaard Stidsen Christian Hove Claussen Erik Max Wulff Lone Pridal Ulla Ribel Jonas Kildegaard Trine Porsgaard Eva Johansson Dorte Bjerre Steensgaard Lars Hovgaard Tine Glendorf Bo Falck Hansen Maja Kirkegaard Jensen Peter Kresten Nielsen Svend Ludvigsen Susanne Rugh Patrick W. Garibay Mary Courtney Moore Alan D. Cherrington Thomas Kjeldsen |
| author_sort | Frantisek Hubálek |
| collection | DOAJ |
| description | Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues. |
| first_indexed | 2024-12-19T08:11:05Z |
| format | Article |
| id | doaj.art-b3637544155945e480839f9c67516402 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-19T08:11:05Z |
| publishDate | 2020-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-b3637544155945e480839f9c675164022022-12-21T20:29:37ZengNature PortfolioNature Communications2041-17232020-07-011111910.1038/s41467-020-17487-9Molecular engineering of safe and efficacious oral basal insulinFrantisek Hubálek0Hanne H. F. Refsgaard1Sanne Gram-Nielsen2Peter Madsen3Erica Nishimura4Martin Münzel5Christian Lehn Brand6Carsten Enggaard Stidsen7Christian Hove Claussen8Erik Max Wulff9Lone Pridal10Ulla Ribel11Jonas Kildegaard12Trine Porsgaard13Eva Johansson14Dorte Bjerre Steensgaard15Lars Hovgaard16Tine Glendorf17Bo Falck Hansen18Maja Kirkegaard Jensen19Peter Kresten Nielsen20Svend Ludvigsen21Susanne Rugh22Patrick W. Garibay23Mary Courtney Moore24Alan D. Cherrington25Thomas Kjeldsen26Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Novo Nordisk A/S, Novo Nordisk Park 1Vanderbilt UniversityVanderbilt UniversityNovo Nordisk A/S, Novo Nordisk Park 1Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues.https://doi.org/10.1038/s41467-020-17487-9 |
| spellingShingle | Frantisek Hubálek Hanne H. F. Refsgaard Sanne Gram-Nielsen Peter Madsen Erica Nishimura Martin Münzel Christian Lehn Brand Carsten Enggaard Stidsen Christian Hove Claussen Erik Max Wulff Lone Pridal Ulla Ribel Jonas Kildegaard Trine Porsgaard Eva Johansson Dorte Bjerre Steensgaard Lars Hovgaard Tine Glendorf Bo Falck Hansen Maja Kirkegaard Jensen Peter Kresten Nielsen Svend Ludvigsen Susanne Rugh Patrick W. Garibay Mary Courtney Moore Alan D. Cherrington Thomas Kjeldsen Molecular engineering of safe and efficacious oral basal insulin Nature Communications |
| title | Molecular engineering of safe and efficacious oral basal insulin |
| title_full | Molecular engineering of safe and efficacious oral basal insulin |
| title_fullStr | Molecular engineering of safe and efficacious oral basal insulin |
| title_full_unstemmed | Molecular engineering of safe and efficacious oral basal insulin |
| title_short | Molecular engineering of safe and efficacious oral basal insulin |
| title_sort | molecular engineering of safe and efficacious oral basal insulin |
| url | https://doi.org/10.1038/s41467-020-17487-9 |
| work_keys_str_mv | AT frantisekhubalek molecularengineeringofsafeandefficaciousoralbasalinsulin AT hannehfrefsgaard molecularengineeringofsafeandefficaciousoralbasalinsulin AT sannegramnielsen molecularengineeringofsafeandefficaciousoralbasalinsulin AT petermadsen molecularengineeringofsafeandefficaciousoralbasalinsulin AT ericanishimura molecularengineeringofsafeandefficaciousoralbasalinsulin AT martinmunzel molecularengineeringofsafeandefficaciousoralbasalinsulin AT christianlehnbrand molecularengineeringofsafeandefficaciousoralbasalinsulin AT carstenenggaardstidsen molecularengineeringofsafeandefficaciousoralbasalinsulin AT christianhoveclaussen molecularengineeringofsafeandefficaciousoralbasalinsulin AT erikmaxwulff molecularengineeringofsafeandefficaciousoralbasalinsulin AT lonepridal molecularengineeringofsafeandefficaciousoralbasalinsulin AT ullaribel molecularengineeringofsafeandefficaciousoralbasalinsulin AT jonaskildegaard molecularengineeringofsafeandefficaciousoralbasalinsulin AT trineporsgaard molecularengineeringofsafeandefficaciousoralbasalinsulin AT evajohansson molecularengineeringofsafeandefficaciousoralbasalinsulin AT dortebjerresteensgaard molecularengineeringofsafeandefficaciousoralbasalinsulin AT larshovgaard molecularengineeringofsafeandefficaciousoralbasalinsulin AT tineglendorf molecularengineeringofsafeandefficaciousoralbasalinsulin AT bofalckhansen molecularengineeringofsafeandefficaciousoralbasalinsulin AT majakirkegaardjensen molecularengineeringofsafeandefficaciousoralbasalinsulin AT peterkrestennielsen molecularengineeringofsafeandefficaciousoralbasalinsulin AT svendludvigsen molecularengineeringofsafeandefficaciousoralbasalinsulin AT susannerugh molecularengineeringofsafeandefficaciousoralbasalinsulin AT patrickwgaribay molecularengineeringofsafeandefficaciousoralbasalinsulin AT marycourtneymoore molecularengineeringofsafeandefficaciousoralbasalinsulin AT alandcherrington molecularengineeringofsafeandefficaciousoralbasalinsulin AT thomaskjeldsen molecularengineeringofsafeandefficaciousoralbasalinsulin |